Siga Technologies (SIGA) Total Non-Current Liabilities (2010 - 2025)
Siga Technologies' (SIGA) quarterly Total Non-Current Liabilities came in at $18.0 million in Q4 2025, down 28.97% on a YoY basis from $25.3 million in Q4 2024, and down 27.57% quarter-over-quarter from $24.8 million in Q3 2025.
Analysis
Siga Technologies (SIGA) Total Non-Current Liabilities (2010 - 2025) Analysis & Trends
Siga Technologies (SIGA) has reported Total Non-Current Liabilities for 16 consecutive years, with $18.0 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities fell 28.97% year-over-year to $18.0 million; the trailing twelve-month figure through Dec 2025 stood at $18.0 million (down 28.97% YoY), and the FY2025 full-year result was $18.0 million, down 28.97% from the prior year.
- Total Non-Current Liabilities eased to $18.0 million in Q4 2025 per SIGA's latest filing, from $24.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $74.8 million in Q1 2024 and bottomed at $10.4 million in Q1 2021.
- Historically, Total Non-Current Liabilities has averaged $25.7 million across 5 years, with a median of $22.5 million in 2021.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities jumped 304.9% in 2024, then slumped 62.84% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $33.9 million in 2021, then tumbled by 36.51% to $21.5 million in 2022, then jumped by 151.5% to $54.1 million in 2023, then plunged by 53.19% to $25.3 million in 2024, then fell by 28.97% to $18.0 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $18.0 million, $24.8 million, and $22.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 106.45 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 16.16 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 100.86 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 32.04 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 1.53 Bn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 1.40 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 607.80 Mn |
| 10 | Siga Technologies | 220.19 Mn | 65.22 Mn | - | 17.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 17.99 Mn |
| Sep 30, 2025 | 24.84 Mn |
| Jun 30, 2025 | 22.72 Mn |
| Mar 31, 2025 | 27.80 Mn |
| Dec 31, 2024 | 25.33 Mn |
| Sep 30, 2024 | 22.30 Mn |
| Jun 30, 2024 | 21.38 Mn |
| Mar 31, 2024 | 74.81 Mn |
| Dec 31, 2023 | 54.12 Mn |
| Sep 30, 2023 | 30.74 Mn |
| Jun 30, 2023 | 18.99 Mn |
| Mar 31, 2023 | 18.48 Mn |
| Dec 31, 2022 | 21.52 Mn |
| Sep 30, 2022 | 27.46 Mn |
| Jun 30, 2022 | 16.69 Mn |
| Mar 31, 2022 | 10.64 Mn |
| Dec 31, 2021 | 33.89 Mn |
| Sep 30, 2021 | 22.66 Mn |
| Jun 30, 2021 | 11.67 Mn |
| Mar 31, 2021 | 10.36 Mn |